891 related articles for article (PubMed ID: 31367247)
1. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
[No Abstract] [Full Text] [Related]
2. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.
Lin X; Yuan G; Yang B; Xie C; Zhou Z; Liu Y; Liu Z; Wu Z; Akimoto Y; Li N; Xu R; Song F
Phytomedicine; 2024 Jul; 129():155559. PubMed ID: 38579642
[TBL] [Abstract][Full Text] [Related]
3. Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca
Zou B; Zheng J; Deng W; Tan Y; Jie L; Qu Y; Yang Q; Ke M; Ding Z; Chen Y; Yu Q; Li X
Phytomedicine; 2021 Jan; 80():153377. PubMed ID: 33126167
[TBL] [Abstract][Full Text] [Related]
4. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
[TBL] [Abstract][Full Text] [Related]
5. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
[TBL] [Abstract][Full Text] [Related]
6. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
[TBL] [Abstract][Full Text] [Related]
7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
8. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
[No Abstract] [Full Text] [Related]
9. Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation.
Xu Y; Song D; Lin X; Peng H; Su Y; Liang J; Hai N; Zhao J; Liu Q
Free Radic Biol Med; 2023 Feb; 196():121-132. PubMed ID: 36649902
[TBL] [Abstract][Full Text] [Related]
10. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
11. Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways.
Sun Y; Liu Y; He W; Wang C; Tickner J; Kuek V; Zhou C; Wang H; Zou X; Hong Z; Yang F; Shao M; Chen L; Xu J
J Cell Physiol; 2019 Jul; 234(7):11792-11804. PubMed ID: 30515822
[TBL] [Abstract][Full Text] [Related]
12. Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways.
Cheng J; Zhou L; Liu Q; Tickner J; Tan Z; Li X; Liu M; Lin X; Wang T; Pavlos NJ; Zhao J; Xu J
J Cell Physiol; 2018 Mar; 233(3):2502-2512. PubMed ID: 28771720
[TBL] [Abstract][Full Text] [Related]
13. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
14. Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling.
Xiao Y; Li K; Wang Z; Fu F; Shao S; Song F; Zhao J; Chen W; Liu Q; Xu J
J Cell Physiol; 2019 Aug; 234(8):13959-13968. PubMed ID: 30633330
[TBL] [Abstract][Full Text] [Related]
15. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
16. Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis.
Kim M; Kim HS; Kim JH; Kim EY; Lee B; Lee SY; Jun JY; Kim MB; Sohn Y; Jung HS
BMC Complement Med Ther; 2020 Feb; 20(1):35. PubMed ID: 32024503
[TBL] [Abstract][Full Text] [Related]
17. MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL-Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway.
Wang Y; Li X; Zhou S; Li J; Zhu Y; Wang Q; Zhao F
Oxid Med Cell Longev; 2022; 2022():7727006. PubMed ID: 36148414
[TBL] [Abstract][Full Text] [Related]
18. A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-
Wong P; Lv Z; Li J; Wei Q; Xu L; Fang B; Luo Y; He M
Oxid Med Cell Longev; 2022; 2022():5982014. PubMed ID: 36388169
[TBL] [Abstract][Full Text] [Related]
19. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
[TBL] [Abstract][Full Text] [Related]
20. Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.
Li S; Teguh D; Wu D; Liu L; Hu C; Yuan J; Inderjeeth CA; Xu J
J Cell Physiol; 2023 Aug; 238(8):1823-1835. PubMed ID: 37334837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
